Get the Stockscreener App
6.40
0.93%
-0.06
Evolus Inc stock is traded at $6.40, with a volume of 1.20M.
It is down -0.93% in the last 24 hours and down -1.54% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$6.46
Open:
$6.46
24h Volume:
1.20M
Relative Volume:
0.88
Market Cap:
$413.99M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-5.9259
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-11.36%
1M Performance:
-1.54%
6M Performance:
-47.02%
1Y Performance:
-61.79%
1-Day Range:
$6.165
$6.485
1-Week Range:
$6.08
$7.385
52-Week Range:
$5.71
$17.44
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.40 | 417.87M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
144.13 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.43 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.3835 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.93 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
How Evolus Inc. (EVL) stock expands through international marketsTrade Exit Report & Comprehensive Market Scan Insights - newser.com
How Evolus Inc. (EVL) stock behaves in tightening cyclesWeekly Volume Report & Entry and Exit Point Strategies - newser.com
What is the fair value estimate for Evolus Inc. (EVL) stock in 2025Analyst Upgrade & Short-Term High Return Strategies - newser.com
Applying Wyckoff theory to Evolus Inc. stockLayoff News & Verified Momentum Stock Alerts - newser.com
Despite shrinking by US$49m in the past week, Evolus (NASDAQ:EOLS) shareholders are still up 92% over 5 years - simplywall.st
What margin trends mean for Evolus Inc. stockWeekly Profit Analysis & AI Based Trade Execution Alerts - newser.com
Full technical analysis of Evolus Inc. stockPortfolio Update Summary & Short-Term Trading Alerts - newser.com
Evaluating Evolus Inc. with trendline analysis2025 Top Gainers & Real-Time Market Trend Scan - newser.com
Will Evolus Inc. stock go up soonDay Trade & AI Forecasted Entry/Exit Points - newser.com
Pinnacle Associates Ltd. Makes New Investment in Evolus, Inc. $EOLS - MarketBeat
Can Evolus Inc. stock reach $100 price target2025 Price Targets & Fast Entry High Yield Stock Tips - newser.com
Is Evolus Inc. still worth holding after the dipWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Real time social sentiment graph for Evolus Inc.Trade Volume Summary & Fast Entry High Yield Tips - newser.com
Evolus, Inc. $EOLS Shares Acquired by Y Intercept Hong Kong Ltd - MarketBeat
What machine learning models say about Evolus Inc.Earnings Risk Summary & Smart Swing Trading Alerts - newser.com
Is Evolus Inc. stock attractive for hedge fundsWatch List & Consistent Growth Equity Picks - newser.com
How high can Evolus Inc. stock goWeekly Investment Summary & Free Real-Time Volume Trigger Notifications - newser.com
Short interest data insights for Evolus Inc.Entry Point & AI Forecasted Entry/Exit Points - newser.com
Advanced analytics toolkit walkthrough for Evolus Inc.Weekly Trend Summary & Long-Term Capital Growth Ideas - newser.com
Will Evolus Inc. rebound enough to break evenJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
Can Evolus Inc. stock resist sector downturnsJuly 2025 Movers & Precise Swing Trade Entry Alerts - newser.com
Applying sector rotation models to Evolus Inc.2025 AllTime Highs & Stepwise Trade Signal Implementation - newser.com
Evolus (EOLS) to Release Earnings on Wednesday - MarketBeat
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - sharewise.com
Evolus, Inc. (NASDAQ:EOLS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):